FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Lignende værker

• FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
  af: Summers, Jeff, et al.
  Udgivet: (2010)
• FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
  af: Nair, Abhilasha, et al.
  Udgivet: (2020)
• FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
  af: Fashoyin‐Aje, Lola, et al.
  Udgivet: (2018)
• FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
  af: Kasamon, Yvette L., et al.
  Udgivet: (2017)
• FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
  af: Larkins, Erin, et al.
  Udgivet: (2017)